NEW DRUG APPROVED

20/09/2016

Labatec Pharma is pleased to announce the launch of : 

Lutrate Depot® 3.75 mg and 22.5 mg : powder and solvent for suspension for injection in symptomatic palliative treatment of advanced hormone-dependent prostate carcinomas

Binosto® 70 mg : alendronic acid, weekly tablets, bone metabolism regulator, bisphosphonates

 

02/06/2016 -

Labatec Pharma is pleased to announce that we have received recently the Marketing Authorization from Swissmedic for :

Binosto® 70 mg : alendronic acid, weekly tablets, bone metabolism regulator, bisphosphonates

Lutrate depot® Labatec 3.75 mg and 22.5 mg : powder and solvent for suspension for injection 

Anastrozol Labatec®, film-coated tablet

Colistilab®,powder for solution for nebuliser

Cefepim Labatec® 1g & 2 g, powder for solution for injection or infusion

 

New products available in the Market :

In oncology

In Anesthesia :

In Anti-infective :


In TB drugs : Rifampicine 150 and 300 mg also available in pack of 20 and 10. 

Please contact our team  in Geneva for ordering information